Ethical aspects of hemophilia gene therapy: a qualitative interview study with stakeholders.
ethics
freedom
gene therapy
hemophilia
qualitative research
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
29
03
2023
revised:
25
08
2023
accepted:
23
09
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
There are great expectations for the potential role of gene therapy in the treatment of hemophilia. At the same time, developments in the field of hemophilia gene therapy have always raised ethical issues. It remains unknown how these ethical issues are perceived by stakeholders, particularly regarding the most recent developments in the field. To obtain insight into stakeholders' morally reasoned opinions on gene therapy for hemophilia. We conducted qualitative research with Dutch people with hemophilia ( We identified 3 main themes. The theme Stakeholders embrace the theoretical potential of gene therapy, while several people with hemophilia question the added value of the current gene transfer products for themselves.
Sections du résumé
Background
UNASSIGNED
There are great expectations for the potential role of gene therapy in the treatment of hemophilia. At the same time, developments in the field of hemophilia gene therapy have always raised ethical issues. It remains unknown how these ethical issues are perceived by stakeholders, particularly regarding the most recent developments in the field.
Objectives
UNASSIGNED
To obtain insight into stakeholders' morally reasoned opinions on gene therapy for hemophilia.
Methods
UNASSIGNED
We conducted qualitative research with Dutch people with hemophilia (
Results
UNASSIGNED
We identified 3 main themes. The theme
Conclusion
UNASSIGNED
Stakeholders embrace the theoretical potential of gene therapy, while several people with hemophilia question the added value of the current gene transfer products for themselves.
Identifiants
pubmed: 38077815
doi: 10.1016/j.rpth.2023.102237
pii: S2475-0379(23)00497-1
pmc: PMC10704513
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102237Investigateurs
M H Cnossen
(MH)
S H Reitsma
(SH)
Informations de copyright
© 2023 The Authors.
Références
J Thromb Haemost. 2023 Mar;21(3):413-420
pubmed: 36696181
J Clin Ethics. 2010 Summer;21(2):133-9
pubmed: 20866019
Blood. 2021 Sep 16;138(11):923-931
pubmed: 34232980
Orphanet J Rare Dis. 2022 Apr 4;17(1):155
pubmed: 35379267
J Deaf Stud Deaf Educ. 2011 Fall;16(4):494-511
pubmed: 21690208
Res Pract Thromb Haemost. 2021 Aug 03;5(5):e12567
pubmed: 34377886
Nat Rev Drug Discov. 2018 Jul;17(7):493-508
pubmed: 29880919
J Thromb Haemost. 2022 Jun 2;:
pubmed: 35652368
J Res Nurs. 2020 Dec;25(8):652-661
pubmed: 34394687
Haemophilia. 2021 Jan;27(1):120-128
pubmed: 33216422
Qual Health Res. 2016 Nov;26(13):1802-1811
pubmed: 27340178
Nurs Open. 2021 May;8(3):1444-1451
pubmed: 33405396
J Neurol Neurosurg Psychiatry. 2001 May;70(5):649-56
pubmed: 11309460
Mol Ther. 2021 Feb 3;29(2):464-488
pubmed: 33309881
J Med Ethics. 2012 Jul;38(7):408-12
pubmed: 22431560
Lancet. 2021 Feb 13;397(10274):630-640
pubmed: 33460559
Res Pract Thromb Haemost. 2022 Apr 12;6(3):e12695
pubmed: 35434467
Haemophilia. 2008 Jan;14(1):5-14
pubmed: 18005150
Camb Q Healthc Ethics. 2012 Oct;21(4):436-47
pubmed: 22828038
Haemophilia. 2021 Sep;27(5):760-768
pubmed: 34265145
Ther Adv Rare Dis. 2021 Sep 26;2:26330040211047244
pubmed: 37181114
Haemophilia. 2003 Mar;9(2):145-52
pubmed: 12614364
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Qual Health Res. 2017 Mar;27(4):591-608
pubmed: 27670770
Haemophilia. 2021 Jan;27(1):129-136
pubmed: 33161616
Am J Mens Health. 2019 Jul-Aug;13(4):1557988319872626
pubmed: 31451017